NCT01617239View on ClinicalTrials.gov

Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Virosomal influenza vaccine

"Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~* 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~* 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)"

Trial Locations (1)

2610

Center for the Evaluation of Vaccination, Unit of Epidemiology and Social Medicine, University of Antwerp, Antwerp

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT01617239 - Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine | Biotech Hunter | Biotech Hunter